KymetaTM Expands Its Next Generation Solutions with Commercial Availability of the u8 GOV Terminal and u8 GO
9.2.2021 17:00:00 EET | Business Wire | Press release
Kymeta (www.kymetacorp.com)—the communications company making mobile global—announced today the expansion and availability of its KymetaTM u8 product, including the Kymeta u8 GOV terminal with an embedded iDirect 950mp modem and the u8 GO transportable terminal. Kymeta u8 GOV terminals are designed to meet the needs of government, military and specialized commercial use and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005134/en/
The u8 GOV terminal and u8 GO provide the complete connectivity solution for on-the-go communications. (Photo: Business Wire)
The u8 GOV terminal includes a FIPS, 140-2 level 3 TRANSEC module and meets the demands of tactical users in scenarios that require secure data, voice, and video connectivity in highly mobile military, government and other rapid response applications. The u8 GOV terminal covers the full Ku-band and is available today as a turnkey terminal with a satellite modem, cellular modem, and SD-WAN capabilities. It is compliant with existing security requirements as defined by the National Institute of Standards and Technology (NIST).
“Kymeta’s solutions meet the mission-critical needs of military, first responders, and commercial customers providing ‘always-on’ connectivity for mobile platforms, making communications on the move more seamless and reliable than ever,” said Rob Weitendorf, Vice President, Business Development, Kymeta.
Also available today, the u8 GO transportable terminals come in multiple configurations including ODU, Commercial and GOV terminals, and enable safe transport with a hardened and rugged shipping case for protection and provide a built-in vehicle mount to support easy communications on the pause (COTP) and communications on-the-move (COTM). This transportable configuration is easily maneuverable and ideal for rapid deployments and has been tested against military transportation standards including MIL-STD-810H, Transit Drop, Transportation Shock, and Loose Cargo Vibration. The u8 GO includes an outdoor AC/DC power supply, supports communications on the pause (COTP) with a 25-degree tilt mechanism, and can also be mounted on a vehicle for easy deployment in a multitude of use cases.
The Kymeta u8 solutions, which now also include the u8 GOV terminal and u8 GO transportable case, provide a complete connectivity solution for communications-on-the-move (COTM) and networks-on-the-move (NOTM) when and where you need it most. The u8 terminal, with Kymeta’s revolutionary software-defined, electronic beam-steering technology, is low profile and easy-to-mount on vehicles and vessels. The u8 turnkey solutions come in multiple terminal configurations that provide customers with the hardware, software, and connectivity they need.
Kymeta recently launched its next-generation antenna, terminal, and services in Q4 of 2020, and has received an overwhelmingly positive response from the industry. The Kymeta u8 terminal paired with Kymeta’s hybrid satellite-cellular connectivity services, Kymeta Connect™, transforms the purchase and consumption of mobile data with all-inclusive hardware, connectivity, and services monthly subscription. The Kymeta u8 is the world’s only commercially available flat-panel electronically steered antenna built specifically for mobility and designed for the needs of military, first responders, and commercial customers.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005134/en/
Contact information
Business Inquiries for Kymeta:
Jon Maron
Vice President of Marketing and Communications
Kymeta Corporation
+1 425.658.8827
jmaron@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Associated Director PR, The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom